EMPA-KIDNEY is the largest and broadest dedicated SGLT2 inhibitor trial to date. It included 6,609 participants across a wide range of underlying causes, many with co-morbidities across the spectrum ...

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced positive top-line results from EMPA-REG OUTCOME ®. This is a long-term clinical trial investigating cardiovascular (CV) ...

CHICAGO, IL—Among patients with chronic kidney disease (CKD) who are at risk for progression, yet another sodium-glucose cotransporter 2 (SGLT2) inhibitor has been shown to improve clinical outcomes.

Researchers running the EMPA-KIDNEY trial that's been testing the safety and efficacy of the SGLT2 inhibitor empagliflozin (Jardiance) in about 6600 patients with chronic kidney disease (CKD) ...

NEW ORLEANS — The potential mechanisms by which the sodium-glucose cotransporter-2 (SGLT-2) inhibitor empagliflozin (Jardiance, Lilly/Boehringer Ingelheim) may have reduced cardiovascular death in the ...

With a European approval for chronic kidney disease nod in hand, Boeringer Ingelheim and Eli Lilly's Jardiance is looking to catch up to AstraZeneca's Farxiga in this use and continue growing its ...

Please provide your email address to receive an email when new articles are posted on . Data were derived from Herrington WG, et al. FR-OR68. Presented at: ASN Kidney Week; Nov. 3-6, 2022; Orlando ...

- EMPA-KIDNEY, the largest and broadest dedicated SGLT2 inhibitor trial in chronic kidney disease, provides new evidence for patients commonly seen in clinical practice - Phase III trial also ...

- EMPA-KIDNEY, the largest and broadest dedicated SGLT2 inhibitor trial in chronic kidney disease, provides new evidence for patients commonly seen in clinical practice - Phase III trial also ...